Larimar Therapeutics Inc. Files Prospectus for Public Offering, Raising Approximately $64.4 Million

Reuters
31 Jul
Larimar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Files Prospectus for Public Offering, Raising Approximately $64.4 Million

Larimar Therapeutics Inc. has filed a prospectus supplement with the Securities and Exchange Commission as part of its public offering of common stock. The company plans to issue and sell 18,750,000 shares at a price of $3.20 per share, with an option for underwriters to purchase an additional 2,812,500 shares. The total net proceeds from the offering, after expenses, are expected to be approximately $64.4 million. The offering is being managed by Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities, Inc., and William Blair & Company, L.L.C., and is set to close pending customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-169818), on July 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10